4results about How to "Increase dose" patented technology

This invention discloses a high-crack-resistant cement-fly ash stabilized base course material, belonging to the field of road engineering technology. The material comprises the following components by mass percentage: 2.0-3.0% cement, 16-20% fly ash, and the balance being stabilized aggregate. The cement is an external admixture, the fly ash is an internal admixture, and the gradation of the stabilized aggregate conforms to the specifications of CF-A-2L or CF-A-2S in JTG / T F20-2015. This invention, by adopting a "low cement, high fly ash" mix design, controls the 7-day unconfined compressive strength within a reasonable range of 3.5-4.5 MPa, effectively avoiding the problem of regular transverse cracks in the base course caused by excessively high early strength. Simultaneously, the high fly ash content ensures the continuous growth of the material's later strength, with its 21-day unconfined compressive strength remaining stable above 6 MPa. Its overall performance is superior to the mix ratios recommended by current standards. This invention is particularly suitable for highway base course construction in arid regions with large temperature differences, such as Xinjiang.

This invention provides a recombinant acetyl-CoA carboxylase encoding gene and its applications. Mutations at positions 5374, 5229, 5335, 5336, and 5493 in the recombinant acetyl-CoA carboxylase encoding gene provided by this invention can induce more significant resistance in rice expressing this recombinant acetyl-CoA carboxylase. In particular, it shows a significant increase in resistance to seven ACCase inhibitors from three major chemically distinct classes: arbutin (APP), quizalofop-P-ethyl, quizalofop-P-ethyl, and flupyrflupyr; cyclohexenone (CHD), clethodim and clodinafop-P-ethyl; and neophenylpyrazoline (DEN), clodinafop-P-ethyl.

The invention discloses a composition for promoting aquatic animal body surface tissue repair and a preparation method and application thereof.The composition is prepared from active ingredients, a biological adhesive and a protein stabilizer, the active ingredients are trachinotus ovatus recombinant IGF1 protein and trachinotus ovatus recombinant IGF2 protein, and the biological adhesive is a biological adhesive. The trachinotus ovatus recombinant IGF1 protein is a fusion protein containing an amino acid sequence as shown in SEQ ID NO: 2, and the N end of the trachinotus ovatus recombinant IGF1 protein is connected with an SUMO tag protein; the invention further discloses a preparation method of the composition for promoting aquatic animal body surface tissue repair and application of the composition in preparation of aquatic animal body surface tissue repair drugs. The composition has the advantages of fusion expression, stability, high efficiency, synergistic repair, low dosage, high efficiency, biological adhesion, long-acting slow release and the like.

This invention discloses a drug-coated balloon catheter with retrievable drugs, comprising a catheter and a balloon unit. The balloon unit includes first to fifth balloons. The first balloon is fitted at the distal end of the catheter to carry the drug. The second and third balloons are fitted at the proximal and distal ends of the first balloon, respectively. The fourth and fifth balloons are fitted at the proximal and distal ends of the second and third balloons, respectively. When the drug-coated balloon catheter is in the closed state, all five balloons are in a contracted state. When in the drug release state, the second and third balloons expand and adhere to the blood vessel wall to form a working area, so that the drug released by the expanded first balloon is blocked in the working area and will not be lost to other places with the blood flow. In the drug retrieval state, the first to third balloons are in a closed state, and the fourth and fifth balloons are in an expanded state to adhere to drugs, thrombi, or plaques floating in the blood vessel, ensuring the quality of vascular interventional treatment and reducing the risk of blockage.